drugset / Trial / NCT00887445

First in Man Study With SLV341

NCT00887445 ↗

Phase 1 Terminated 87 enrolled Solvay Pharmaceuticals Quintiles, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

First in man study with single and multiple rising doses with SLV341

Timeline

Start
2008-07
Primary completion
2009-05
Completion
2009-05

Outcome

Outcome not reported

Stopped (Business): “The study was terminated on June 25th, 2009 due to strategic decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject SLV341 Unknown 5 mg —
Subject SLV341 Unknown 1000 mg —

Indications